Testicular cancer: Understanding tumor markers and hormone tests

A hand holds an open blank book with three colored windows.

Tumor markers and sex hormones have different roles in testicular cancer care. AFP, beta-hCG, and LDH help assess and monitor certain germ cell tumors. Testosterone and estradiol more often describe hormonal effects of the disease or its treatment. Normal results in either group do not reliably rule out testicular cancer. A new lump or persistent change in a testicle needs examination regardless of a blood test.

Testicular cancer and its measurable signals

The main established serum tumor markers are alpha-fetoprotein, or AFP, human chorionic gonadotropin, or hCG/beta-hCG, and lactate dehydrogenase, or LDH. Certain nonseminomatous tumor components can produce AFP. Tumor cells with the relevant differentiation can produce hCG. LDH is an enzyme found in many tissues and may rise with increased cell turnover, among other causes.

These results complement examination, ultrasound, tissue findings, and imaging. They can contribute to assessing disease extent and risk, and to evaluating treatment. A trend is often more informative than one value because production, clearance, and other conditions affect the concentration. See the testicular cancer review and tumor-marker guideline. The current EAU diagnostic guidance also describes their role before and after surgery.

Markers do not directly count every tumor cell in real time. Not every germ cell tumor raises them, and an abnormal result can have another cause. A pure seminoma does not produce AFP; elevated AFP therefore calls for consideration of other tumor components or a non-tumor explanation, among other possibilities. LDH is particularly nonspecific. See the germ cell tumor review.

Why testosterone and estradiol also matter

Tumor markers do not answer the same question as sex hormones. Testosterone and estradiol can help evaluate hormonal consequences of the disease, surgery, or chemotherapy. These may affect libido, energy, blood formation, muscles, and bones.

A low testosterone value may fit with symptoms, but does not by itself prove a deficiency requiring treatment or testicular cancer. Interpretation considers symptoms, repeat measurements under appropriate conditions, and sometimes other hormones such as LH and FSH. After removal of one testicle, the remaining testicle can often take over its function; monitoring depends on the course and symptoms. See the systematic review of long-term effects.

Units and the laboratory method are essential when reading a hormone result. A number without units cannot be interpreted as a testosterone range, and vague descriptions such as estradiol in the low tens are not useful without a defined assay and reference interval. There is also no generally established rule that every man feels best in the middle or upper half of a testosterone range.

In men, much estradiol is produced by conversion of androgens in different tissues. It is not produced exclusively, or predominantly directly, in the testicles. Low estrogen levels can also affect bones and sexual function, so making estradiol as low as possible is not a general goal.

Elevated hCG can alter hormonal activity and be associated with breast tenderness or gynecomastia. It can stimulate steroid production through LH receptors. Saying that hCG always lowers the body’s testosterone therefore does not reliably describe what can happen. The pattern needs to be interpreted with LH, testosterone, estradiol, and the clinical situation.

In adolescents, hormonal reference ranges differ by pubertal stage. Delayed development or growth concerns require age-appropriate endocrine assessment rather than applying an adult cutoff.

What hormone results contribute to care

Testosterone is important to many functions and forms part of the feedback system connecting the brain, pituitary gland, and testicles. Estradiol contributes to bone health, among other roles. Disease and treatment can change both, but so can body weight, medicines, acute illness, and the timing of blood collection.

An unremarkable hormone result does not automatically mean fertility and every testicular function are normal. Sperm production and hormone production are different jobs. If you want children or are preparing for treatment that could affect fertility, discuss fertility preservation early with the care team. The NCI treatment information includes this issue.

A useful monitoring plan starts with the question: is it investigating a possible germ cell tumor, following a known cancer, or assessing symptoms of hormone deficiency? A general testosterone-and-estradiol package does not replace specific tumor evaluation.

Frequently asked questions

What does a blood test for suspected testicular cancer include?

Depending on the situation, AFP, beta-hCG, and LDH are measured. They complement physical examination and testicular ultrasound. Testosterone or estradiol may be added for a hormonal question, but they are not reliable tests for excluding cancer.

A suspicious examination or ultrasound finding still needs investigation when every marker is within its reference range.

Why are these results measured?

Tumor markers can help characterize certain tumor types, assess risk, and follow treatment response. Sex hormones mainly help identify functional consequences. Both can be valuable, but they should not be combined under the same promise of a cancer blood test.

Can blood be collected at home?

Depending on local services, a properly organized venous blood draw may be possible at home. The right laboratory, correct sample handling, and a plan to discuss the result matter. Home collection does not replace examination or ultrasound for a new testicular finding.

How often should testing happen?

These sources do not establish routine tumor-marker screening for the general population. After confirmed testicular cancer, follow-up depends on tumor type, stage, treatment, and the surveillance protocol.

When testosterone deficiency is suspected, morning measurements on separate days may improve interpretation. That is different from cancer surveillance; do not choose monitoring intervals independently from a general article.

What can affect the results?

Sex hormones vary with time of day, age, acute illness, and medicines. Testosterone products, anabolic steroids, opioids, and glucocorticoids are important to report. Alcohol, body weight, and liver, kidney, or thyroid conditions may also contribute to the picture.

AFP can be elevated with liver disease, for example. LDH rises with many forms of tissue injury and with hemolysis of the sample. Biotin can interfere with some immunoassays. An unexpected finding should therefore be checked for plausibility without delaying a necessary cancer investigation.

How should I prepare for testosterone and estradiol measurements?

For testosterone, morning collection under comparable conditions is often useful, commonly before 10 a.m. The practice or laboratory should explain whether fasting is required and how medicines should be handled. An acute illness can make interpretation harder.

There is no single preparation rule covering every assay. A prescribed fasting period or a pause in vigorous exercise, alcohol, or biotin needs to fit the specific test. Biotin instructions particularly depend on dose, kidney function, and method. Do not stop prescribed medicines on your own; list all products and doses for the care team.

Can lifestyle changes affect the values?

Yes. Sleep, body weight, training load, and alcohol can influence sex hormones. An improvement may matter for well-being. It does not prove that a tumor has disappeared or that an elevated tumor marker was harmless.

Do not try to treat tumor markers through a personal optimization experiment. A change needs the appropriate medical explanation.

How do I read my report?

Look at the marker name, units, reference range, date, and reason for testing. Low or undetectable AFP and hCG can be reassuring in the right clinical course, but do not exclude every active cancer. Normal testosterone and estradiol do not establish freedom from a tumor either.

A low testosterone result or unusual hormone pattern is assessed alongside symptoms and, if needed, further tests. The next step follows from the whole picture: examination, ultrasound, tumor markers, and other imaging when indicated.